Diagnosticos da America S.A.

As of June 30, 2026, Diagnosticos da America S.A. carries a market capitalization of 3.39B, placing it among publicly traded companies globally. Its enterprise value stands at 9.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Diagnosticos da America S.A.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Diagnosticos da America S.A. has 1.25B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.36, and the price-to-book ratio stands at 0.50.

As of June 30, 2026, Diagnosticos da America S.A. trades at an EV/EBITDA multiple of 6.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.83B versus a market cap of 3.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Diagnosticos da America S.A. maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 107.43, indicating elevated leverage, while an interest coverage ratio of 1.26 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Diagnosticos da America S.A. posted a negative return on equity (ROE) of -12.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.79, reflecting losses generated across the asset base. The company generates approximately 513,972.44 in revenue per employee across its workforce of 18,142.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 29.71 indicates how many times Diagnosticos da America S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Diagnosticos da America S.A. recorded 179.38M in income tax expense. The company reported a pretax loss of -697.12M and -895.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Diagnosticos da America S.A.'s stock has gained approximately 257.45% over the past 52 weeks. The 50-day moving average sits at 3.41, while the 200-day moving average is 3.34.

Over the twelve months ended June 30, 2026, Diagnosticos da America S.A. generated 9.32B in revenue and converted that into -895.11M in net income, yielding earnings per share of -0.70. EBITDA reached 1.57B, while operating income came in at 714.60M.

As of June 30, 2026, Diagnosticos da America S.A. holds 958.70M in cash and equivalents against 7.38B in total debt, resulting in a net debt position of 5.20B. Total book value stands at 6.84B, with working capital of 921.14M providing operational flexibility.

Diagnosticos da America S.A. produced 435.63M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -187.20M in capital expenditures, free cash flow totaled 248.43M - equivalent to 0.20 per share.

Over the twelve months ended June 30, 2026, Diagnosticos da America S.A. posted a gross margin of 31.02, reflecting its pricing power and cost economics. The operating margin of 7.66 and net profit margin of -9.60 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Diagnosticos da America S.A. paid dividends of 0.00 per share. The dividend payout ratio of -0.56 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 67.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Diagnosticos da America S.A. shareholders.

Diagnosticos da America S.A.'s most recent stock split took place on February 2, 2010 with a 1:4 split ratio.

As of June 30, 2026, Diagnosticos da America S.A. has an Altman Z-Score of 0.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.